Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Automotive & E-Mobility

Tech-Heavy Nasdaq 100 Defies Market Weakness to Seal Record Close

Robert Sasse by Robert Sasse
September 15, 2025
in Automotive & E-Mobility, Nasdaq, Tech & Software
0
NASDAQ 100 Stock
0
SHARES
142
VIEWS
Share on FacebookShare on Twitter

In a striking display of divergence, the Nasdaq 100 index powered to a fresh all-time high on Friday, closing with a gain of 99.63 points, or 0.42%, to finish the session at 24,092.19. This advance occurred against a backdrop of broader market weakness, with both the Dow Jones and the S&P 500 posting losses for the day. The tech-centric index’s resilience was largely fueled by a powerful surge in heavyweight constituent Tesla, marking a notable outperformance amid rising bond yields and deteriorating consumer sentiment.

Selective Rally Driven by Mega-Caps

The trading session revealed a market of two tales. While the Nasdaq 100 not only closed at a record but also hit a new intraday peak of 24,137.06, the broader market faced significant pressure. The day’s negative market breadth, where declining issues outnumbered advancing ones by a factor of 1.77, highlights that the day’s gains were highly concentrated in a handful of mega-cap technology stocks.

Despite the churn beneath the surface, market volatility remained remarkably subdued. The CBOE Nasdaq 100 Volatility Index (VXN), often called the fear gauge for the index, actually declined by 0.27% to settle at 18.18.

Tesla Ignites the Rally: Top Performers and Laggards

The primary engine behind the index’s climb was Tesla, whose shares skyrocketed 7.4% following a show of strong support for CEO Elon Musk from the company’s board chairman.

A review of the session’s biggest movers reveals a diverse list of top performers:

Should investors sell immediately? Or is it worth buying NASDAQ 100?

  • Warner Bros. Discovery: +17.0%
  • Tesla: +7.4%
  • Micron Technology: +7.0%
  • Apple: +1.5%
  • Microsoft: +1.2%

Conversely, the sell-off was most pronounced in the biotechnology and software sectors, with the steepest declines seen in:

  • Arista Networks: -8.9%
  • Moderna: -7.4%
  • Oracle: -5.1%
  • Netflix: -3.0%

Technical Outlook: Bulls Maintain Firm Control

From a technical perspective, the bulls are firmly in command. The index concluded the week decisively above its key moving averages—the 50-day at 23,804 and the 200-day at 23,552—and successfully breached the psychologically significant 24,000 level.

Although the Relative Strength Index (RSI) reading of 67.38 suggests the index is approaching overbought territory, the underlying momentum appears intact for now. The immediate resistance level to watch is 24,150, with support likely to be found at 24,103 and more substantially near the 23,500 mark.

Early indications from E-Mini futures point toward a tentative start for the coming Monday, potentially signaling a pause for breath after the record-setting run.

Ad

NASDAQ 100 Stock: Buy or Sell?! New NASDAQ 100 Analysis from March 25 delivers the answer:

The latest NASDAQ 100 figures speak for themselves: Urgent action needed for NASDAQ 100 investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

NASDAQ 100: Buy or sell? Read more here...

Tags: NASDAQ 100
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock
AI & Quantum Computing

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Technology Select Sector SPDR® Fund Stock
AI & Quantum Computing

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

March 25, 2026
Next Post
PepGen Stock

PepGen Shares Surge Amidst High Volatility and Analyst Optimism

Mirion Technologies Stock

Inclusion in S&P SmallCap 600 Index Fuels Mirion Technologies' Momentum

Carvana Stock

Carvana Stock: Insider Sales Clash with Analyst Confidence

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com